Yeah interesting point Stez. I know nothing about EIQ, only...

Yeah interesting point Stez. I know nothing about EIQ, only heard of them just now. But it begs the question of how EBR will behave when approval is for the WiSE device is granted (assuming it is). JM has been pretty (extremely?) bullish on our chances of FDA approval, so I wonder how much of our SP at the time will have that baked in? How will the SP behave when it happens - what will one's strategy be? Sell the news? Hold on no matter what? Accumulate? Sell a portion and carry the rest?

Everyone will have a different plan and GLA, personally (and assuming I can be at the screen on the day) at this stage I'll probably sell a small portion at whatever I assess to be the high of the day (rightly or wrongly), and then reassess depending on how things behave in the short term after that.

For interests sake here are a few examples of how ASX listed medical/biotech stocks have behaved around the FDA approval process. SP numbers given may not be exact, but close enough to give an idea.


NEUREN (NEU)
I was involved in this one. The stock did very little leading up to the announcement. In fact it had driften from 9.00 to 7.50 in the weeks prior. Trading halt Friday 10/3/23. Approval announced on Monday 13/3. There's a jump from 7.60 to 9.30 on the open, stock peaks at 9.70, but closes at 9.09. In the days that follow however, the stock continues to rally to settle around the 13.50 mark over the following weeks. Interestingly (and depressingly for me as a holder) the stock finds itself at roughly the same level today 18 months later despite almost entierly positive newsflow.

BOTANIX (BOT)
This was BOTs second crack at approval for Sofpironium (the first was denied because of what I understand to be some 'labelling issues' essentially) so perhaps there was much value baked in. The stock jumps from .355 to .36 (bugger all) on approval day, rallies a little the next day, peaks at .40, but then drifts lower. 4 months later, the BOT still sits at .385. FDA approval was not exactly the launchpad holders may have been hoping for, but then, it was their second bite at the cherry, and the stock had run up from a low of .12 after approval was denied the first time 9 months earlier.



GENETIC SIGNATURES LIMITED (GSS)
Approval for GSSs Easyscreen leads to an SP jump from a previous close of .73 to .79 at the open, rallies to .85, but closes back at .75, only .02c above the price pre-approval. Interestingly, a far bigger jump happened months earlier at the end of Feb with no obvious catalysts. There were no price sensitive announcements at all in the yellow box. On 22/2 a Half yearly/Market Update was released - blue $. Was this jump beginning days after that due a big player taking a position, or was it because a director bought 60k shares on-market on 29/2 (orange +)?



ECHOIQ LTD (EIQ)
This is the example Stezza mentioned today. A huge rally in the weeks leading up to approval (approx .16 to .24), then another jump on the day of approval from .24 to .28 on open, closing at .31. Despite the bullish candle (closing on daily high), the stock drops 5% the next day (today). Where to from here? Will it do an NEU and continue to rally over the coming weeks, or a BOT/GSS and fall away?



There are probably loads of recent examples of FDA approval on the ASX and how it plays out. I'm interested to hear what others expect or are planning for with regards to EBR given what we now so far, as well as any experiences others may have to share. GLA